drugset / Trial / NCT05035914
Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer
Phase 1/2
Unknown
94 enrolled
Guangzhou University of Traditional Chinese Medicine
Guangdong Provincial Hospital of Traditional Chinese Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
1. Determine the maximum tolerable dose (MTD) and / or phase II recommended dose (RP2D) of the allotinib combined mXELIRI protocol. 2. To evaluate the safety and tolerance of the combination of anlotinib and mXELIRI in the second-line treatment of patients with advanced colorectal cancer
Timeline
- Start
- 2021-07-09
- Primary completion
- 2022-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |